Marrone Bio Innovations Inc (NASDAQ:MBII) – Investment analysts at Jefferies Financial Group issued their Q1 2019 EPS estimates for Marrone Bio Innovations in a report released on Monday, April 29th, Zacks Investment Research reports. Jefferies Financial Group analyst L. Alexander expects that the basic materials company will earn ($0.04) per share for the quarter. Jefferies Financial Group also issued estimates for Marrone Bio Innovations’ Q2 2019 earnings at ($0.05) EPS and Q3 2019 earnings at ($0.05) EPS.
Marrone Bio Innovations (NASDAQ:MBII) last posted its quarterly earnings data on Thursday, May 9th. The basic materials company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). Marrone Bio Innovations had a negative net margin of 82.82% and a negative return on equity of 123.95%. The business had revenue of $8.72 million for the quarter, compared to analyst estimates of $6.18 million.
Separately, National Securities reaffirmed a “buy” rating and issued a $2.50 target price on shares of Marrone Bio Innovations in a report on Friday, May 10th.
Marrone Bio Innovations stock traded down $0.03 during trading hours on Tuesday, hitting $1.65. The stock had a trading volume of 54,742 shares, compared to its average volume of 128,944. The company has a debt-to-equity ratio of 2.47, a quick ratio of 1.47 and a current ratio of 1.94. The stock has a market capitalization of $186.01 million, a PE ratio of -7.86 and a beta of -0.12. Marrone Bio Innovations has a 12-month low of $1.10 and a 12-month high of $2.18.
A number of institutional investors have recently modified their holdings of the business. BlackRock Inc. raised its holdings in Marrone Bio Innovations by 0.5% in the fourth quarter. BlackRock Inc. now owns 2,800,519 shares of the basic materials company’s stock worth $4,117,000 after buying an additional 14,014 shares during the last quarter. Northern Trust Corp raised its holdings in Marrone Bio Innovations by 3.1% in the first quarter. Northern Trust Corp now owns 538,681 shares of the basic materials company’s stock worth $824,000 after buying an additional 16,161 shares during the last quarter. Rhumbline Advisers raised its holdings in Marrone Bio Innovations by 44.3% in the fourth quarter. Rhumbline Advisers now owns 68,021 shares of the basic materials company’s stock worth $100,000 after buying an additional 20,882 shares during the last quarter. Geode Capital Management LLC raised its holdings in Marrone Bio Innovations by 5.8% in the fourth quarter. Geode Capital Management LLC now owns 443,611 shares of the basic materials company’s stock worth $652,000 after buying an additional 24,460 shares during the last quarter. Finally, Raymond James & Associates purchased a new position in Marrone Bio Innovations in the first quarter worth about $41,000. 42.18% of the stock is owned by institutional investors and hedge funds.
About Marrone Bio Innovations
Marrone Bio Innovations, Inc provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation.